Dr. Woldu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-8765Fax+1 214-645-8769
Summary
- Dr. Solomon Woldu is an urologist in Dallas, TX and is affiliated with multiple hospitals in the area, including William P. Clements, Jr. University Hospital, Parkland Health & Hospital System, JPS Health Network, and Veterans Affairs North Texas Health Care System. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 7 years. He specializes in surgical oncology and is experienced in urology and urologic neoplasms.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Minimally Invasive Urologic Surgery, 2016 - 2018
New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 2011 - 2016- New York Presbyterian HospitalInternship, Transitional Year, 2010 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2010
Washington University in St. LouisB.A., Biology, 2002 - 2006
Certifications & Licensure
TX State Medical License 2016 - 2025
American Board of Urology Urology
Clinical Trials
- Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer Start of enrollment: 2021 Sep 06
- Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma Start of enrollment: 2021 Nov 29
Publications & Presentations
PubMed
- Editorial Comment.Yair Lotan, Solomon Woldu
The Journal of Urology. 2025-03-01 - Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure.Thomas Gerald, Solomon L Woldu, Daniel Halstuch, Yaara Ber, Karin Lifshitz
Urologic Oncology. 2025-02-15 - Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer.Zine-Eddine Khene, Raj Bhanvadia, Sarah Attia, Willian Ito, Ivan Trevino
The Journal of Urology. 2025-02-10
Authored Content
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
- Multi-Institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial CarcinomaMay 2018
Press Mentions
Socioeconomic Factors Linked to Immunotherapy Use in Urologic CancersSeptember 10th, 2024- Socioeconomic Disparities Impact Immunotherapy Use in Urologic CancersSeptember 9th, 2024
- Widespread Disparities Exist in Treating Advanced CancersSeptember 4th, 2024
- Join now to see all
Grant Support
- T32 GrantNational Institute of Health2016–2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
